Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fagus grandifolia pollen is an allergenic extract derived from the pollen of the Fagus grandifolia plant, also known as the American beech tree. [12] It is a biologic product approved under a Biologic License Application and has been marketed since 1941. This extract is used for both diagnosing and treating immediate hypersensitivity allergies to beech tree pollen. [1, 3] As a diagnostic tool, it is applied via skin tests to confirm sensitivity. [1, 3, 5] For therapeutic purposes, it is used in allergen immunotherapy, where repeated and gradually increasing doses are administered to desensitize the immune system. [1, 3] This desensitization process works by modulating the body's immune response to the pollen, particularly by shifting away from an IgE-mediated allergic reaction towards a state of tolerance. [1, 14]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fagus grandifolia pollen extract.